Aberrant expression of intelectin-1 in gastric cancer: its relationship with clinicopathological features and prognosis

Purposes Human intelectin-1 (ITLN-1) is a novel identified galactose-binding lectin that is expressed in the colonic goblet cells. Since gastric adenocarcinomas can arise through a process of intestinalization, we speculate that ITLN-1 may be aberrantly expressed in gastric cancer. This study was un...

Full description

Saved in:
Bibliographic Details
Published in:Journal of cancer research and clinical oncology 2012, Vol.138 (1), p.163-172
Main Authors: Zheng, Liduan, Weng, Mixia, Qi, Meng, Qi, Teng, Tong, Ling, Hou, Xiaohua, Tong, Qiangsong
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Antineoplastic agents
Biological and medical sciences
Cancer
Cancer Research
Cell Growth Processes - physiology
Cytokines - biosynthesis
Cytokines - genetics
Female
Gastroenterology. Liver. Pancreas. Abdomen
Gastrointestinal diseases
Gene expression
GPI-Linked Proteins - biosynthesis
GPI-Linked Proteins - genetics
Hematology
Humans
Immunohistochemistry
Internal Medicine
Intestinal Mucosa - metabolism
Intestinal Mucosa - pathology
Lectins - biosynthesis
Lectins - genetics
Male
Medical prognosis
Medical sciences
Medicine
Medicine & Public Health
Metaplasia
Middle Aged
Oncology
Original Paper
Pathology
Pharmacology. Drug treatments
Real-Time Polymerase Chain Reaction
Stomach Neoplasms - genetics
Stomach Neoplasms - metabolism
Stomach Neoplasms - pathology
Stomach. Duodenum. Small intestine. Colon. Rectum. Anus
Survival Rate
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purposes Human intelectin-1 (ITLN-1) is a novel identified galactose-binding lectin that is expressed in the colonic goblet cells. Since gastric adenocarcinomas can arise through a process of intestinalization, we speculate that ITLN-1 may be aberrantly expressed in gastric cancer. This study was undertaken to examine the ITLN-1 expression in gastric cancer and correlate it with clinical outcomes. Methods One hundred and ninety-six gastric cancer patients were evaluated for the ITLN-1 expression by immunohistochemistry. The ITLN-1 transcripts were measured by real-time quantitative PCR. Results ITLN-1 expression was absent in normal gastric mucosa, whereas areas of intestinal metaplasia revealed ITLN-1 immunoreactivity. One hundred and forty-two gastric cancer patients (72.4%) were positive for ITLN-1 expression. In a subtotal of 20 patients, ITLN-1 transcripts were significantly enhanced in gastric cancer tissues than in normal gastric mucosa ( P  
ISSN:0171-5216
1432-1335
DOI:10.1007/s00432-011-1088-8